Join us for an insightful interview with Invion Limited (ASX: IVX) with host James Whelan, as he discusses the progress of next-generation Photodynamic Therapy (PDT) technology and Invion Limited’s activity updates with Thian Chew, Executive Chair and CEO of Invion Limited.

In this engaging conversation, Thian Chew talks about Invion Limited's innovative approach to targeting cancer cells while activating the immune system, offering a promising alternative to traditional therapies like chemotherapy and radiotherapy. He shares highlights from the recently published Activity Report, including signing a collaboration agreement with a major leading South Korean company and the imminent commencement of skin cancer trials.

For further information on this Investment Opportunity, please contact James Whelan.

Read the Conversation:

Hello and welcome to another corporate showcase. My name is James Whelan, managing director of Barclay Pierce Capital's wealth management division, joined here by the head of Invion Limited, Thian Chew. Invion Limited, a next generation, with their next-generation PDT technology, focused on killing just cancer cells and activating the immune system in comparison to chemo and radiotherapy being available.

We're going to go into that in just a second. Also, if you want to value them on other companies, they are undervalued compared to other companies as well. We will get into that too. First off, I'm going to introduce Thian Chew, head of  Invion Limited. As I said, Thian, how are you now?

Good, James. How about you? Really good to talk to you though. We don't get enough chances to catch up. Now, uh, you mentioned undervaluation versus other players in the market. Um, when we were talking earlier today, just wanted to, if you had a chance to go into that. So if you look at the statistics, one in a thousand companies actually even get to a phase one clinical trial.

Once you get to a clinical trial, one in 10 get approved. Those are the statistics. That's why when you've got a company that's at clinical trial stage, it's significantly de-risked versus something at an earlier stage. And we're about to, um, move forward and, uh, commence a number of clinical trials in multiple cancer indications, which is essentially where the biggest, uh, unmet need in R and D and in healthcare is right now.  That's it's going to be exciting to see what comes up out of that. And I will be following that quite closely with, um, with my clients as well that we have and our advisors in that too. Now you've just had a recently published activity report.

I'm going to let you continue the show here and talk to it. Um, because you definitely know the details about that, but it seemed fairly positive from what I'm reading here.  Well, it's been an interesting quarter and it's, it's really a culmination of all the things we've been working on for the past couple of years.

And, uh, one of the items is we're, uh, we're essentially on the cusp of essentially starting our, uh, our first clinical trial, which is in non-melanoma skin cancers. Uh, we are waiting for, um, the, uh, ethics, uh, feedback, in which case, uh, we'll be ready to go. Uh, surely after that. So I think that that's certainly one of the catalysts that investors look for.

But the second, um, um, uh, catalyst. The second interesting update was we've done some work with the Peter McCallum Cancer Center on combining our therapy with, uh, a type of immunotherapy called checkpoint inhibitors, which is essentially the, uh, the main blockbuster drug in cancer. Today, uh, it accounts for billions of dollars of revenue.

And, um, when they work, they work really well. Uh, the problem is that they response rates typically not that high. It can be as low as 12 percent or lower. And what we did with Peter Mac was we found that, um, the standalone, um, was consistent with, with industry at about 12%. Um, but when we did it in combination with our PDT, we increased that to 80 percent response rate.

And this was done in a mouse model. Uh, using an anal squamous cell carcinoma model, um, which, uh, you know, we were pretty excited. Peter Mac is really excited. So we're looking to integrate some of these outcomes into our, you know, upcoming clinical trials. And hopefully we could increase and improve the response rate for, um, the ability to activate immune, uh, the immune system when fighting cancers, because that's ultimately where, where you can get sustained sort of, uh, uh, regression and, uh, and tumor sort of, uh, treatment.

Excellent. And, uh, I believe there was a collaboration announced.  Yes, there was as well. So this was actually outside cancer, and this is actually outside the, uh, the cancer, compound we're using INB043. Um, we have a portfolio of about over 300, uh, novel compounds. And, uh, we signed with a South Korean company called Dr.IMB.  Which actually has experience with PDT as well. They looked at our data, they liked what they saw, and basically they committed to funding and running development process in Korea with gynecological hospitals and looking at doing proof of concept clinical trials. Uh, for HPV, uh, virus, which is a, a very pro it's actually the most prevalent STD highly prevalent in this part of the world.

Hmm. Yeah, and it sounds like good progress in that regard as well, especially with the collaboration. Now the process for skin track skin cancer trials coming up. Um, The expected start date, maybe not be so specific, but yeah, look, look, we're, we're, we're hoping, I mean, we, we, we have, uh, submitted to the ethics committee.

We, uh, we have a site, we have a protocol, we, uh, kind of, we're kind of just raring to go, uh, but we do need to get the thumbs up before we can move forward. And we're hoping we're, uh, we're relatively not too far away from doing that. I'm looking forward to seeing that kickoff and then the results that will come after that as well, uh, confident.

So thank you for joining us, uh, Thain Chew of Invion Limited for this corporate showcase, uh, anyone who wants to know more about the story, please contact myself or any of the links that we're going to be posting on this one. Uh, the, the, when it is released. Um, and generally speaking, please feel free to reach out because this really is a great story doing some amazing things.

Um, the technology that they have is the, the, the PDT is, you know, Is phenomenal and really needs to be known about, about how much more advanced I believe that it isn't. And the initial testing has shown that it is. So, um, really is a good one. Thank you very much for joining us Thian. And I hope that you have yourself a good afternoon. 

Great. Thanks very much, James.